Literature DB >> 21881361

Mitral valve repair in a patient with myelodysplastic syndrome.

Tadashi Omoto1, Masanori Hirota, Noboru Ishikawa, Takeo Tedoriya.   

Abstract

Open heart operations for patients with myelodysplastic syndrome (MDS) are associated with infective and bleeding complications. We report a 67-year-old woman with rheumatic, severe mitral regurgitation and mitral stenosis associated with MDS who underwent a mitral valve (MV) repair. Commissurotomy was performed in the anterior commissure. Autologous pericardial patch treated with glutaraldehyde solution was prepared. The anterior leaflet was completely detached from the posterior to the anterior commissure. The anterior leaflet was augmented by autologous pericardial patch treated with glutaraldehyde solution and three pairs of artificial chordae were implanted. Postoperative transesophageal echocardiography showed an increase in the MV orifice and less than trivial mitral regurgitation. Two years after the operation, the patient has normal sinus rhythm with no deterioration of the MV lesion by transthoracic echocardiography. Although the feasibility of MV repair is low in patients with restrictive pathology due to rheumatic disease, MV repair may be preferred in patients with MDS.

Entities:  

Mesh:

Year:  2011        PMID: 21881361     DOI: 10.5761/atcs.cr.10.01643

Source DB:  PubMed          Journal:  Ann Thorac Cardiovasc Surg        ISSN: 1341-1098            Impact factor:   1.520


  2 in total

1.  Transcatheter aortic valve implantation in a patient with aplastic anemia.

Authors:  Yujiro Kawai; Yasuyuki Toyoda; Hikaru Kimura; Miki Horigome; Yasutoshi Tsuda; Takahiro Takemura
Journal:  J Cardiol Cases       Date:  2017-09-05

2.  Minimally invasive mitral valve repair via right mini-thoracotomy in patient with myelodysplastic syndrome.

Authors:  Takura Taguchi; Hiroyuki Nishi; Kimihiro Kurose; Kohei Horikawa; Go Kanazawa; Toshiki Takahashi
Journal:  J Cardiothorac Surg       Date:  2018-05-18       Impact factor: 1.637

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.